Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing

Initial clients reporting commercial success, revolutionizing indication selection of lead programs

Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals

WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sarborg Limited ("Sarborg" or the "Company"), a technology-driven company that integrates mathematical algorithm-led approaches with complementary cybernetics to optimize decision-making processes, is pleased to announce the successful closing of its $10 million Seed funding round, led by third-party investor, Corvus Capital.

Sarborg has achieved significant commercial and technical milestones from its development plan, since its inception in 2024. The issuance of $10 million of Convertible Promissory Notes highlights investor confidence in Sarborg's novel approach and rapid development delivering commercial milestones.

Looking forward, the proceeds of the fundraising will enable Sarborg to scale its AI-driven drug development and deploy agents across expanded client portfolios, while diversifying its client and equity partnership base. Sarborg ...